[go: up one dir, main page]

MX360877B - Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il) -3,4-dihidropirazino[2,3-b]pirazin-(1h)-ona para usarse en el tratamiento de sarcoma de ewing que sobreexpresa e-veintiseis(ets). - Google Patents

Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il) -3,4-dihidropirazino[2,3-b]pirazin-(1h)-ona para usarse en el tratamiento de sarcoma de ewing que sobreexpresa e-veintiseis(ets).

Info

Publication number
MX360877B
MX360877B MX2014011117A MX2014011117A MX360877B MX 360877 B MX360877 B MX 360877B MX 2014011117 A MX2014011117 A MX 2014011117A MX 2014011117 A MX2014011117 A MX 2014011117A MX 360877 B MX360877 B MX 360877B
Authority
MX
Mexico
Prior art keywords
ets
veintiseis
dihydropirazine
pirazin
piridin
Prior art date
Application number
MX2014011117A
Other languages
English (en)
Other versions
MX2014011117A (es
Inventor
Xu Shuichan
Mae Hege Kristen
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of MX2014011117A publication Critical patent/MX2014011117A/es
Publication of MX360877B publication Critical patent/MX360877B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G01N33/57557—

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proporcionan en la presente métodos para tratar o prevenir el sarcoma de Ewing que sobreexpresa E-veintiséis (ETS), que comprende administrar una cantidad efectiva de un inhibidor de TOR cinasa a un paciente que tiene sarcoma de Ewing que sobreexpresa E-veintiséis (ETS).
MX2014011117A 2012-03-15 2013-03-14 Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il) -3,4-dihidropirazino[2,3-b]pirazin-(1h)-ona para usarse en el tratamiento de sarcoma de ewing que sobreexpresa e-veintiseis(ets). MX360877B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611370P 2012-03-15 2012-03-15
US201261715329P 2012-10-18 2012-10-18
PCT/US2013/031202 WO2013138556A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014011117A MX2014011117A (es) 2015-04-08
MX360877B true MX360877B (es) 2018-11-21

Family

ID=47998542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011117A MX360877B (es) 2012-03-15 2013-03-14 Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il) -3,4-dihidropirazino[2,3-b]pirazin-(1h)-ona para usarse en el tratamiento de sarcoma de ewing que sobreexpresa e-veintiseis(ets).

Country Status (20)

Country Link
US (1) US20130245029A1 (es)
EP (1) EP2825168B1 (es)
JP (2) JP2015516375A (es)
KR (3) KR102057358B1 (es)
CN (2) CN107137402A (es)
AU (1) AU2013203156C1 (es)
BR (1) BR112014022697A2 (es)
CA (1) CA2867349A1 (es)
EA (1) EA028434B1 (es)
ES (1) ES2677908T3 (es)
IL (2) IL234640B (es)
MX (1) MX360877B (es)
MY (1) MY182650A (es)
NI (1) NI201400109A (es)
NZ (1) NZ628421A (es)
PH (2) PH12014502048B1 (es)
SG (1) SG11201405706TA (es)
TW (2) TWI600428B (es)
WO (1) WO2013138556A1 (es)
ZA (1) ZA201406709B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AR094494A1 (es) 2013-01-16 2015-08-05 Signal Pharm Llc Pirrolopirimidinas sustituidas, sus composiciones, y sus métodos de tratamiento
EP2986319A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
SG11201508223YA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CN106715427A (zh) 2014-07-14 2017-05-24 西格诺药品有限公司 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法
PH12019501350B1 (en) * 2016-12-20 2024-02-23 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
BR202019004173Y1 (pt) 2018-03-01 2024-02-20 Essilor International Dispositivo óptico
EP3759545B1 (en) 2018-03-01 2023-12-20 Essilor International Lens element
CN113493471B (zh) * 2020-04-03 2024-06-11 山东轩竹医药科技有限公司 杂芳环类激酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717773A2 (pt) 2006-10-19 2013-11-05 Signal Pharm Llc Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase
EP2078016B1 (en) * 2006-10-19 2012-02-01 Signal Pharmaceuticals LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
ES2751705T3 (es) 2009-10-26 2020-04-01 Signal Pharm Llc Métodos de síntesis y purificación de compuestos heteroarilo
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
EP2825168B1 (en) 2018-05-09
HK1201755A1 (en) 2015-09-11
KR20200034818A (ko) 2020-03-31
KR20190058673A (ko) 2019-05-29
AU2013203156B2 (en) 2015-12-10
IL234640A0 (en) 2014-11-30
US20130245029A1 (en) 2013-09-19
TWI664968B (zh) 2019-07-11
EA028434B1 (ru) 2017-11-30
MY182650A (en) 2021-01-27
AU2013203156A1 (en) 2013-10-03
PH12018502234A1 (en) 2019-08-14
KR102057358B1 (ko) 2019-12-18
TW201343167A (zh) 2013-11-01
ES2677908T3 (es) 2018-08-07
JP2015516375A (ja) 2015-06-11
NZ628421A (en) 2016-04-29
IL234640B (en) 2020-05-31
PH12018502234B1 (en) 2021-07-23
CN104302295B (zh) 2017-06-20
AU2013203156C1 (en) 2016-02-18
EA201491694A1 (ru) 2015-06-30
SG11201405706TA (en) 2014-10-30
TWI600428B (zh) 2017-10-01
CN104302295A (zh) 2015-01-21
TW201733586A (zh) 2017-10-01
WO2013138556A1 (en) 2013-09-19
BR112014022697A2 (pt) 2020-06-30
PH12014502048B1 (en) 2020-10-28
CA2867349A1 (en) 2013-09-19
PH12014502048A1 (en) 2014-12-10
MX2014011117A (es) 2015-04-08
CN107137402A (zh) 2017-09-08
NI201400109A (es) 2015-01-15
JP6470821B2 (ja) 2019-02-13
EP2825168A1 (en) 2015-01-21
JP2018065820A (ja) 2018-04-26
IL274318A (en) 2020-06-30
ZA201406709B (en) 2016-07-27
KR20140138929A (ko) 2014-12-04

Similar Documents

Publication Publication Date Title
MX360877B (es) Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il) -3,4-dihidropirazino[2,3-b]pirazin-(1h)-ona para usarse en el tratamiento de sarcoma de ewing que sobreexpresa e-veintiseis(ets).
ZA202208792B (en) Methods of treating and preventing graft versus host disease
BR112015020466A2 (pt) inibidores de cdc7
ECSP14017584A (es) Compuestos inhibidores de raf
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12014502047A1 (en) Treatment of cancer with tor kinase inhibitors
MX2013003076A (es) Terapeuticos contra cancer de mama.
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
HK1221144A1 (zh) 用於治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
HK1221150A1 (zh) 用二氢吡嗪并-吡嗪类对癌症的治疗
WO2013185048A3 (en) Heterocyclic guanidine f1f0-atpase inhibitors
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
EA201690327A1 (ru) Терапевтические способы
MX373322B (es) Tratamiento de los síntomas asociados a terapia privación de andrógenos.
MX362111B (es) Un metodo para mejorar la funcion hepatica.
HK1207008A1 (en) Use of thymosin alpha for treatment of purulent rhinosinusitis
HK1228259A1 (en) Methods of treating and preventing graft versus host disease
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы

Legal Events

Date Code Title Description
FG Grant or registration